Leukemia drug heralds molecularly targeted era.
Vastag
B
B
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002892:Chromosomes, Human, Pair 22 / Q000235:genetics; D002899:Chromosomes, Human, Pair 9 / Q000235:genetics; D015507:Drugs, Investigational / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D010677:Philadelphia Chromosome; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D014178:Translocation, Genetic
D000970:Antineoplastic Agents; D015507:Drugs, Investigational; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl